We’re still figuring out the side effects of GLP-1 weight-loss drugs

We have a tendency in tech to look for the silver bullet. In crypto, it was the one-click token that would revolutionize finance. In AI, it is the one-model-fits-all solution. Right now, in the longevity and biotech space, that silver bullet is GLP-1 drugs. You know them by their brand names, but the underlying science is what is actually moving the needle.

The Biological Age Equation

Recent data shared at an aging summit in Boston suggests that these weight-loss drugs are doing more than just suppressing appetite. Researchers are finding that people with obesity or diabetes who take GLP-1s show a biological age that is roughly two to three years younger than their peers who are not on the medication. On paper, that sounds like a miracle. If you can shave three years off your cellular clock by taking a weekly injection, why wouldn't you?

As a founder, I look at this and see a classic optimization problem. We are seeing a measurable improvement in biomarkers, but we are also operating with a massive amount of technical debt. We know what these drugs do to your blood sugar and your waistline, but we are still largely in the dark about the long-term downstream effects on the human operating system.

The Data Gap in Longevity Tech

The problem with the current hype cycle is that we are confusing weight loss with health. If you lose fifty pounds, your biomarkers will obviously improve. Your heart does not have to work as hard, your inflammation drops, and your insulin sensitivity stabilizes. Of course, your "biological age"—a metric that is still somewhat squishy and debated in the scientific community—is going to look better.

But for those of us building in this space, the real question is whether the drug is actually slowing down the aging process or if it is just removing the heavy friction caused by metabolic dysfunction. There is a big difference between fixing a broken engine and simply driving the car downhill so the engine doesn't have to work. We are currently looking at the downhill version.

The Founder's Perspective on Side Effects

In software, when you push a major update to fix a bug, you usually introduce two or three new ones. Human biology is the ultimate legacy codebase. We are seeing reports of muscle loss, gastroparesis, and even mental health shifts. When you dramatically alter the body's signaling system for hunger and satisfaction, you aren't just changing a physical state; you are changing a behavioral loop.

Builders in the health-tech and AI-bio sectors need to be looking at the side effects as a feature, not a bug. They represent the boundaries of what the drug can safely do. If the goal is longevity, a two-year reduction in biological age is a poor trade-off if it comes with a 20% loss in lean muscle mass, which is one of the strongest predictors of survival as we age. We are optimizing for the scale while potentially sabotaging the frame.

Moving Beyond the Hype

The venture capital flowing into GLP-1 adjacent startups is staggering. There are apps to help you manage your dosing, platforms to ship the meds to your door, and coaching programs to help you eat while on them. It feels a lot like the early days of DeFi, where everyone was building wrappers around a core protocol without questioning if the protocol itself was sustainable.

We need to be skeptical of any "fountain of youth" narrative that relies on a lifelong subscription model. True longevity tech should be about metabolic flexibility—the body's ability to handle fuel efficiently on its own. GLP-1s provide metabolic stability, but they do it through external regulation. It is like outsourcing your dev team; it works in the short term, but you lose the internal capability to build and maintain the product.

What Builders Should Focus On

If you are building in this sector, stop trying to be the next pharmacy. Instead, focus on the monitoring and recovery stack. We need better ways to track real-time muscle density and metabolic health that don't rely on basic BMI or flawed biological age tests. We need tools that help users transition off these drugs rather than staying on them forever.

The current research from Boston is an interesting signal, but it is not a conclusion. It tells us that we have found a powerful lever. It does not tell us what happens to the rest of the machine when we pull that lever for twenty years straight. History shows that when we find a shortcut in health, there is usually a toll booth further down the road.

The Skeptic's Takeaway

I am not saying these drugs don't have value. For people facing chronic illness, a three-year reduction in biological age is a massive win. But for the general population looking for a biohack, we need to be careful. We are effectively beta-testing a systemic shift in human metabolism.

For founders and investors, the play isn't just the drug; it is the infrastructure required to manage the fallout. We are creating a new class of patients who are dependent on synthetic hormones to maintain a baseline. That is a huge market, sure, but is it a resilient one? I'd rather see us building tools that help people regain their natural metabolic sovereignty.

The goal of technology should be to enhance human capability, not to replace a fundamental biological function with a subscription service.

We are still in the early innings of understanding how these drugs interact with the aging process. Until we have longitudinal data that accounts for muscle preservation and neurological health, we should treat the "age reversal" claims as a marketing headline rather than a scientific fact. Build for the long term, not the current trend.

Read the original at MIT Technology Review →